
| - | |
|-----------------|----------------|
| | |
| LNCaP vs. MR49F | C4-2 vs. C4-2R |
| SEL1L | UBB |
| FOXA1 | RPS19 |
| RPS27A | MYC |
| RBPJ | GALNT11 |
| SNW1 | APH1A |
| ADAM10 | MIB2 |
| IFT74 | NCSTN |
| MIB1 | APH1B |
| WDR12 | MAML3 |
| MAML1 | PSEN1 |
| RPS19 | EPN1 |
| PSEN2 | PSEN2 |
| NCSTN | SEL1L |
| UBB | CREBBP |
| SUSD5 | POFUT1 |
| MYC | ADAM17 |
| APH1A | RBPJ |
| DTX4 | ITCH |
| IFT172 | NKAP |
| ADAM17 | EP300 |
| GMDS | MAML1 |
| DTX3 | IFT74 |
| NEURL1B | SNW1 |
| UBC | KAT2B |
| GALNT11 | RBM15 |
| APH1B | NOTCH2 |
| CDKN1B | SPEN |
| NKAP | APP |
| ITGB1BP1 | NOTCH3 |
| KAT2B | IFT172 |
| KRT19 | ITGB1BP1 |
| S1PR3 | JAG2 |
| GOT1 | WDR12 |
| MIB2 | JAG1 |
| NLE1 | HES1 |
| POFUT1 | SUSD5 |
| JAG2 | DTX3 |
| NOTCH2 | KRT19 |
| PSEN1 | DTX4 |
| PERP | HNF1B |
| NOTCH1 | RPS27A |
| SPEN | MDK |
| CREBBP | FOXA1 |
| EP300 | ADAM10 |
| APP | GOT1 |
| MDK | NOTCH1 |
| NOTCH3 | UBC |
| SOX9 | GMDS |
| MAML3 | CEBPA |
| JAG1 | PERP |
| UBA52 | CDKN1B |
| ANXA4 | S1PR3 |
| EPN1 | SOX9 |


| DTX2 | NEURL1B |
|--------|---------|
| CEBPA | UBA52 |
| ITCH | PSENEN |
| PSENEN | DTX2 |
| HNF1B | NLE1 |
| RBM15 | MIB1 |
| HES1 | ANXA4 |

Supplemental Table S1. List of differentially expressed genes in LNCaP vs. MR49F and C4-2 vs. C4-2R. The list of genes corresponds to the heatmaps represented in Figures 3A and 3B. Genes are listed in an order matching the representative heatmap.



Supplemental Figure S1. Knockdown of Notch2 induces no changes in cleaved-PARP expression and in cell proliferation. **A,** C4-2R cells were infected with shCtrl or shNotch2 virus particles and selected with

puromycin. Cells were collected and subjected to western blot analysis with indicated antibodies. **B,** Stable C4-2R shCtrl and shNotch2 cells were treated with DMSO or 40 µM enzalutamide for 72 hours and subjected to western blot analysis with indicated antibodies. **C,** Stable C4-2R shCtrl and shNotch2 cells were treated with DMSO or increasing concentrations of enzalutamide and subjected to MTT assay. Optical densities were measured and normalized to DMSO-treated samples.



Supplemental Figure S2. PF-03084014 reduces the expression of Notch signaling downstream targets in enzalutamide-resistant cell lines *in vitro* and *in vivo*. **A, B and C,** MR49F, C4-2R and 22RV1 cells were treated with DMSO, PF-03084014, enzalutamide or both at the indicated concentrations for 72 hours. Cells were collected and subjected to western blot. **D,** Quantification of HES1 positively stained cells (n=3). All groups were normalized to the vehicle control group. * indicates that p-value<0.05, ** indicates that p-value<0.01 and *** indicates that p-value<0.001.